Mankind pharma grey market premium

Shares of Mankind Pharma, a homegrown company that sells condom brand Manforce and pregnancy test kit Prega News, made a positive stock market debut on Tuesday with the stock listing at ₹1,300 on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), a 20.4% premium to its issue price of ₹1,080 pershare. In comparison, the BSE Sensex was trading 190 points, or 0.31%, higher at 61,954 levels. Post listing, the stock touched a high of ₹1,325 on the BSE, while the market capitalisation stood at ₹53,569 crore at the time of reporting. On the volume front, as many as 1.37 crore shares changed hands over the counter on the BSE and the NSE. The strong listing of Mankind Pharma shares was in line with Street expectations as the stock was commanding a premium of ₹120 per equity share in the grey market, a parallel market where deals are done in-person only among the trusted group of investors.This means, Mankind Pharma IPO listing price was pegged at around₹1,200 (₹1,080 +₹120), which is around 11% higher from the IPO price of₹1,080 per share. The Delhi-based company raised ₹4,326 crore in the country’s biggest initial public offering (IPO) so far this year, which received an overwhelming response from qualified institutional investors (QIBs)and non-institutional investors (NIIs), but failed to excite retail investors. The three-day IPO of MankindPharma, which opened for subscription between April 25-27,was subscribed 15.32 times, with the portion reserved for QIBs ...

May 9, 2023 admin [ssba] • • • • Mankind Pharma IPO Particulars & Guidance @ Chanakyanipothi.com, India`s Oldest & the most Trusted Investment website for coming up IPOs. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years. Mankind IPO listing at which price?The scrip will list on 9th May 2023. The grey market of the IPO witnessed sharp volatility. At one time the GMP had declined to Zero and there were no trades seen and then suddenly the GMP shot up to Rs. 73 and gradually improved to current level of Rs. 100/103. However, the traders show complete uncertainty about listing price. The way the promoters are Expert & energetic about the marketing, promotions and new launches, we expect positive listing, not just Rs. 1200, but there are all chances that on listing day, the scrip moves up to Rs. 1400 and yet there are large number of investors and traders who are skeptical of listing. They fear negative listing. Actual Listing: The scrip listed at Rs. 1300 and during the intraday, it moved up to Rs. 1393.65 Whether you should apply in Mankind Pharma IPO? The management has formed habit of very fast and impressive growth. Highly capable of developing strong brands in Pharma and FMCG businesses. Grown organically and is the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in the Financial Year 2022. At a first glance, the price may appear to be high, gr...

Synopsis Mankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to-earnings ratio of 30 times FY22 earnings and has a market capitalisation of Rs 44,000 crore. The initial share sale of the company was subscribed 15.32 times with strong interest from QIBs and is the largest IPO so far this year. The company has 25 manufacturing facilities across India, a dedicated in-house R&D centre and a team of over 600 scientists. However, it is important to note that grey market premiums are just an indicator as to how the company's shares are stacked up in the unlisted market and are subject to change rapidly. Mankind Pharma is valued at a price-to-earnings ratio of 30 times FY22 earnings and commands a market capitalisation of Rs 44,000 crore. Post-IPO, the promoter will hold 78% of the company, with 12% held by existing PE investors. Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for moving annual total as of December 2022. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. Don’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp.

Mankind Pharma IPO: After closure of subscription, bidders and market observers are eagerly ready for announcement of share allotment date, which is more than likely on third May 2023. As per the tentative schedule of this Prega News and Manforce maker firm’s preliminary public providing (IPO), Mankind Pharma IPO allotment date is more than likely on third May 2023. However, those that have utilized for the IPO want to not transfer from pillar to submit as they’ll examine their software standing on-line by logging in on the BSE web site or at official registrar’s web site. Meanwhile, as Mankind Pharma IPO allotment date is quick approaching, gray market has gone bullish on the general public situation because the secondary market has been in uptrend for final six days. According to market observers, shares of Mankind Pharma Ltd can be found at a premium of ₹92 in gray market at this time. Mankind Pharma IPO GMP at this time Market observers stated that Mankind Pharma IPO gray market premium (GMP) at this time is ₹92, which is ₹7 greater from its yesterday’s GMP of ₹85 apiece. They stated that Mankind Pharma IPO GMP has risen from ₹60 to ₹92 in final three days, which is principally because of the pattern reversal on Dalal Street. They stated that bullish sentiments at Indian inventory market has modified gray market sentiments in regard to Mankind Pharma IPO. They stated that Mankind Pharma IPO GMP might additional go upside if the secondary market continues to...

The shares of Mankind Pharma are expected to get listed on both BSE and NSE on Tuesday, May 9. Ahead of the listing, the company's grey market premium, which indicates the premium commanded by shares in the unlisted market, is at 120, which is 20 percent higher than its yesterday's GMP of Rs 100, according to market observers.

Mankind Pharma latest IPO GMP Today is ₹121(+/-), last updated on May 9th 2023 10:18 AM. Given at the price band of 1080, the estimated listing price for the Mankind Pharma IPO is ₹1201 (cap price + today's GMP). The expected gain/loss per share in terms of percentage is 11.20%.• Mankind Pharma IPO Retail Subject to Sauda: ₹950 We update GMP on daily basis and based on the last 25 sessions grey market activities, Today's IPO GMP trend indicates Upside and expects a strong listing. With this, retail investors should apply in this IPO with full force. The lowest GMP is recorded at ₹28 while the highest GMP is ₹140. Stay tuned with us to know the day-by-day Mankind Pharma IPO GMP Performance along with its expected listing price. Mankind Pharma Day-wise IPO GMP Trend GMP Date GMP S2S Estimated Listing Price Last Updated Time 09-05-2023 ₹121 950 ₹1201 (11.20%) 9-May-2023 09:18:16 AM 08-05-2023 ₹140 950 ₹1220 (12.96%) 8-May-2023 07:33:49 PM 07-05-2023 ₹113 950 ₹1193 (10.46%) 7-May-2023 08:00:08 AM 06-05-2023 ₹113 950 ₹1193 (10.46%) 6-May-2023 06:04:00 PM 05-05-2023 ₹92 950 ₹1172 (8.52%) 5-May-2023 05:08:14 PM 04-05-2023 ₹103 950 ₹1183 (9.54%) 4-May-2023 10:00:40 PM 03-05-2023 ₹79 950 ₹1159 (7.31%) 3-May-2023 04:51:17 PM 02-05-2023 ₹82 950 ₹1162 (7.59%) 2-May-2023 05:06:48 PM 01-05-2023 ₹96 950 ₹1176 (8.89%) 1-May-2023 05:25:00 PM 30-04-2023 ₹88 550 ₹1168 (8.15%) 30-Apr-2023 11:05:48 PM 29-04-2023 ₹83 550 ₹1163 (7.69%) 29-Apr-2023 05:15:22 PM 28-04-2023 ₹84 550 ₹1164 (7.78%) 28-...

Mankind Pharma, whose Rs 4,326.36 crore initial public offer (IPO) received a strong response from the investors during the bidding process, is likely to announce its allotment of shares on Wednesday, May 03, 2023. The IPO of India’s fourth largest pharmaceutical company received a strong response from the investors and was overall subscribed 15.32 times. The issue was open for subscription between April 25-27 in the price range of Rs 1,026-1,080 per share. The quota reserved for qualified institutional bidders was subscribed 49.16 times, while the portion for non-institutional bidders was booked 3.80 times. The allocation of retail investors was subscribed 92 per cent. Last head, Mankind Pharma was commanding a premium of Rs 90-100 in the grey market. A majority of the brokerage firms are positive on the issue and suggest investors subscribe to the issue on a long-term basis, citing the dominant market position, strong financials, defensive sector and robust growth outlook. However, some analysts have raised red flags over rich valuations and the complete OFS nature of the issue, capping room for any stellar upside. Investors, who had bid for the issue, can check the allotment status on the Bombay Stock Exchange (BSE) website: 1) Visit https://www.bseindia.com/investors/appli_check.aspx 2) Under the issue type, click Equity 3) Under the issue name, select Mankind Pharma Limited in the dropbox 4) Write the application number 5) Add the PAN card ID 6) Click on 'I am not a...

Mankind Pharma IPO: After closure of subscription, bidders and market observers are eagerly ready for announcement of share allotment date, which is more than likely on third May 2023. As per the tentative schedule of this Prega News and Manforce maker firm’s preliminary public providing (IPO), Mankind Pharma IPO allotment date is more than likely on third May 2023. However, those that have utilized for the IPO want to not transfer from pillar to submit as they’ll examine their software standing on-line by logging in on the BSE web site or at official registrar’s web site. Meanwhile, as Mankind Pharma IPO allotment date is quick approaching, gray market has gone bullish on the general public situation because the secondary market has been in uptrend for final six days. According to market observers, shares of Mankind Pharma Ltd can be found at a premium of ₹92 in gray market at this time. Mankind Pharma IPO GMP at this time Market observers stated that Mankind Pharma IPO gray market premium (GMP) at this time is ₹92, which is ₹7 greater from its yesterday’s GMP of ₹85 apiece. They stated that Mankind Pharma IPO GMP has risen from ₹60 to ₹92 in final three days, which is principally because of the pattern reversal on Dalal Street. They stated that bullish sentiments at Indian inventory market has modified gray market sentiments in regard to Mankind Pharma IPO. They stated that Mankind Pharma IPO GMP might additional go upside if the secondary market continues to stay bullis...

Mankind Pharma latest IPO GMP Today is ₹121(+/-), last updated on May 9th 2023 10:18 AM. Given at the price band of 1080, the estimated listing price for the Mankind Pharma IPO is ₹1201 (cap price + today's GMP). The expected gain/loss per share in terms of percentage is 11.20%.• Mankind Pharma IPO Retail Subject to Sauda: ₹950 We update GMP on daily basis and based on the last 25 sessions grey market activities, Today's IPO GMP trend indicates Upside and expects a strong listing. With this, retail investors should apply in this IPO with full force. The lowest GMP is recorded at ₹28 while the highest GMP is ₹140. Stay tuned with us to know the day-by-day Mankind Pharma IPO GMP Performance along with its expected listing price. Mankind Pharma Day-wise IPO GMP Trend GMP Date GMP S2S Estimated Listing Price Last Updated Time 09-05-2023 ₹121 950 ₹1201 (11.20%) 9-May-2023 09:18:16 AM 08-05-2023 ₹140 950 ₹1220 (12.96%) 8-May-2023 07:33:49 PM 07-05-2023 ₹113 950 ₹1193 (10.46%) 7-May-2023 08:00:08 AM 06-05-2023 ₹113 950 ₹1193 (10.46%) 6-May-2023 06:04:00 PM 05-05-2023 ₹92 950 ₹1172 (8.52%) 5-May-2023 05:08:14 PM 04-05-2023 ₹103 950 ₹1183 (9.54%) 4-May-2023 10:00:40 PM 03-05-2023 ₹79 950 ₹1159 (7.31%) 3-May-2023 04:51:17 PM 02-05-2023 ₹82 950 ₹1162 (7.59%) 2-May-2023 05:06:48 PM 01-05-2023 ₹96 950 ₹1176 (8.89%) 1-May-2023 05:25:00 PM 30-04-2023 ₹88 550 ₹1168 (8.15%) 30-Apr-2023 11:05:48 PM 29-04-2023 ₹83 550 ₹1163 (7.69%) 29-Apr-2023 05:15:22 PM 28-04-2023 ₹84 550 ₹1164 (7.78%) 28-...

Mankind Pharma shares managed to attract single-digit premium in the grey market on the day of price band announcement and ahead of the IPO launch. The expensive valuations and only offer for sale portion in the IPO may be reasons for low premium, experts said. The offer will open for subscription in the coming week on April 25 and the closing date would be April 27, 2023. The pharmaceutical company on April 19 has fixed price band for its IPO at Rs 1,026-1,080 per share. More than 4 crore shares public issue is completely an offer for sale by promoters and investors, which means the company will not get funds through this offer and the entire amount will go to selling shareholders. The public issue in total will fetch the company Rs 4,326.35 crore at higher end of price band. Currently its shares are traded with around 7-8 percent premium in the grey market, analysts said. The grey market is an unofficial trading platform for IPO shares and is generally used by investors to know about expected demand to the issue and listing price. "The current grey market premium of Mankind Pharma of about 7 percent is not encouraging, considering the size of the IPO at about Rs 4,300 crore," Manish Chowdhury, Head of Research at Stoxbox said. He expects the grey market premium to dilute further over the period due to expensive valuations, higher borrowings and no use of proceeds for business purposes. He believes that there are better opportunities in the pharmaceutical space available ...